

Press release 2022-07-05

## AcuCort launches new website

**AcuCort AB (publ) (Spotlight Stock Market: ACUC) announced today that the company's new website with improved functions as well as with new graphic identity and updated content has been launched.**

As part of ensuring good functionality and visualizing that AcuCort takes further steps in its development, the company has developed a new website. The website now offers, for example, functions such as a subscription service for the company's press releases and financial reports, as well as improved IR and corporate governance pages. Other content has also been updated. Please visit [www.acucort.se](http://www.acucort.se).

"AcuCort is well on its way to taking the big step from a development company to an exciting growth company. I see good conditions for a continued positive development of the company and hope that our new website will contribute to increased interest and greater knowledge of AcuCort's operations," says Jonas Jönmark, CEO of AcuCort.

*The information was submitted for publication, through the agency of the contact person below, on July 5, 2022.*

### **For more information, please contact:**

Jonas Jönmark, CEO, AcuCort AB

Telephone: + 46 (0)70 365 5400

Email: [jonas.jonmark@acucort.se](mailto:jonas.jonmark@acucort.se)

### **About AcuCort AB (publ)**

AcuCort has developed and commercializes ISICORT<sup>®</sup>, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT<sup>®</sup> is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT<sup>®</sup> was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company's assessment that the time to commercialization of ISICORT<sup>®</sup> may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit [www.acucort.se](http://www.acucort.se).